Articles published by NImmune Biopharma

Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for Ulcerative Colitis and Crohn’s disease

February 17, 2026

From NImmune Biopharma

Via Business Wire

NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

May 06, 2025

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets

October 23, 2024

From NImmune Biopharma

Via Business Wire

NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium

September 16, 2024

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines

September 05, 2024

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

November 14, 2023

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

October 23, 2023

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

May 17, 2023

From NImmune Biopharma

Via Business Wire

NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline

May 03, 2023

From NImmune Biopharma

Via Business Wire

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease

March 22, 2023

From NImmune Biopharma

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.